A Phase 1 Study To Investigate the Pharmacokinetics of SR Formulations; and the Food Effect, Safety, Tolerance, Pharmacokinetic and Pharmacodynamic Profile Of 1 SR Formulation of EB-1020 In Young Healthy Subjects

Trial Profile

A Phase 1 Study To Investigate the Pharmacokinetics of SR Formulations; and the Food Effect, Safety, Tolerance, Pharmacokinetic and Pharmacodynamic Profile Of 1 SR Formulation of EB-1020 In Young Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 31 May 2014

At a glance

  • Drugs Centanafadine (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Pharmacokinetics
  • Sponsors Neurovance
  • Most Recent Events

    • 04 Feb 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Sep 2013 Planned End Date changed from 1 Jun 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov record.
    • 21 Feb 2013 Status changed from not yet recruiting to recruiting, as reported in a Neurovance media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top